ライフサイエンスコーパス: alpha-emitter

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 years) resemble closely high-redshift Lyman-alpha emitters.

2 for other high-affinity mAbs and short-lived alpha-emitters.

3 demonstrated the therapeutic efficacy of the alpha-emitter (149)Tb and beta(-)-emitter (161)Tb.

4 g-lived beta-emitters (129)I, (36)Cl and the alpha-emitters (154)Dy, (148)Gd, (150)Gd, and (146)Sm fr

5 es were dominated by the naturally occurring alpha-emitter (210)Po and that Fukushima-derived doses w

6 h the beta-emitters (131)I and (90)Y and the alpha-emitter (211)At in patients with recurrent and new

7 emitters (188)Re, (177)Lu, and (90)Y and the alpha-emitters (211)At, (213)Bi, and (212)Pb were compar

8 With the alpha-emitter (213)Bi, significant efficacy was obtained

9 We concluded that alpha-emitter (213)Bi-labeled monoclonal antibody target

10 The alpha-emitter, (213)Bi (T(1/2) = 45.6 min), was conjugat

11 B7 monoclonal antibodies (MAbs) labeled with alpha-emitter 213Bi and Cryptococcus neoformans cells as

12 ination with chemotherapy and the use of the alpha emitter (223)Ra-dichloride in prostate cancer, pri

13 tion at DNA scales was also compared with an alpha emitter, (223)Ra.

14 In addition to being the first approved alpha-emitter, (223)RaCl2 is the first radiopharmaceutic

15 chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recent

16 These findings suggest that alpha-emitters are highly efficacious in MRD settings, w

17 According to the presented model, alpha-emitters are needed to achieve radiation doses hig

18 alpha-emitters are particularly well adapted to this app

19 erapy with an anti-CD45 mAb labeled with the alpha-emitter, astatine-211 ((211)At), as a conditioning

20 ther the short-lived (half-life, 46 minutes) alpha-emitter bismuth 213 ((213)Bi) conjugated to an ant

21 Here, we substituted the alpha-emitter bismuth-213 (213Bi) linked to a monoclonal

22 at pretransplant radioimmunotherapy with the alpha-emitter bismuth-213 (Bi) coupled to anti-CD45 or a

23 Unlike beta particle-emitting isotopes, alpha emitters can selectively kill individual cancer ce

24 uding several promising low-energy beta- and alpha-emitters, for radionuclide therapy.

25 sing targeted radiotherapeutics labeled with alpha-emitters have been developed.

26 Although alpha-emitters have been studied for many decades, their

27 dium-223 dichloride (radium-223), a targeted alpha-emitter, improved overall survival compared with p

28 There are large amounts of heavy alpha-emitters in nuclear waste and nuclear materials in

29 For alpha-emitters, microtumors receive high doses (>20 Gy o

30 Alpha-particle immunotherapy by targeted alpha-emitters or alpha-emitting isotope generators is a

31 Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with

32 icity from longer path lengths compared with alpha emitters such as (211)At, which has a higher energ

33 mans and showed the benefit of instead using alpha-emitters such as (211)At.

34 Radioimmunotherapy using alpha-emitters such as (213)Bi, (211)At, and (225)Ac has

35 are emphasized, and new concepts in targeted alpha-emitter therapy are introduced.

36 sites, making it an optimal method to target alpha-emitters with short half-lives, such as bismuth-21

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。